Overview
Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy
Status:
Unknown status
Unknown status
Trial end date:
2019-04-01
2019-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathyPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Tel-Aviv Sourasky Medical CenterTreatments:
BrinzolamideCriteria
Inclusion Criteria:- Central serous chorioretinopathy (CSC) affecting the fovea, non-resolving after 4
months of follow-up
- Optical coherence tomography (OCT) shows foveal subretinal fluid
- Fluorescein angiography and indocyanine green confirm the diagnosis
Exclusion Criteria:
- Any other ophthalmic condition that may lead to subretinal fluid
- Choroidal neovascularization
- Myopia > -6D
- Previous treatment for CSC in the past 6 months
- Known allergy to fluorescein or indocyanin green
- Known allergy for brinzolamide
- Pregnancy, breast feeding